Advanced search
Publication Cover
Cancer Biology & Therapy Volume 25, 2024 - Issue 1
Submit an article Journal homepage
1,597
Views
0
CrossRef citations to date
0
Altmetric
Research Paper

Prognostic value of pretreatment procalcitonin and neutrophil–lymphocyte ratio in extensive-stage small-cell lung cancer

Dongfang ChenDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaView further author information
,
Jianlin XuDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaView further author information
,
Yizhuo ZhaoDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaView further author information
,
Baohui HanDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaCorrespondence[email protected]
View further author information
&
Runbo ZhongDepartment of Respiratory and Critical Care Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, ChinaCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4616-1224View further author information
ORCID Icon
Article: 2331273 | Received 22 Feb 2023, Accepted 12 Mar 2024, Published online: 27 Mar 2024

References

  • Kahnert K, Kauffmann-Guerrero D, Huber RM. SCLC-State of the art and what does the future have in store? Clin Lung Cancer. 2016;17(5):325–6. doi:10.1016/j.cllc.2016.05.014.
  • van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–1755. doi:10.1016/S0140-6736(11)60165-7.
  • Gong J, Salgia R. Managing Patients With Relapsed Small-Cell Lung Cancer. J Oncol Pract. 2018;14(6):359–366. doi:10.1200/JOP.18.00204.
  • Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899. doi:10.1016/j.cell.2010.01.025.
  • Sakin A, Sahin S, Yasar N, Demir C, Arici S, Geredeli C, Cihan S. The relation between hemogram parameters and survival in extensive-stage small cell lung cancer. Oncol Res Treat. 2019;42(10):506–515. doi:10.1159/000501595.
  • Heper Y, Akalin EH, Mistik R, Akgoz S, Tore O, Goral G, Oral B, Budak F, Helvacı S. Evaluation of serum C-reactive protein, procalcitonin, tumor necrosis factor alpha, and interleukin-10 levels as diagnostic and prognostic parameters in patients with community-acquired sepsis, severe sepsis, and septic shock. Eur J Clin Microbiol Infect Dis. 2006;25(8):481–491. doi:10.1007/s10096-006-0168-1.
  • Patout M, Salaun M, Brunel V, Bota S, Cauliez B, Thiberville L. Diagnostic and prognostic value of serum procalcitonin concentrations in primary lung cancers. Clin Biochem. 2014;47(18):263–267. doi:10.1016/j.clinbiochem.2014.09.002.
  • Cate CC, Pettengill OS, Sorenson GD. Biosynthesis of procalcitonin in small cell carcinoma of the lung. Cancer Res. 1986;46(2):812–818.
  • Walter MA, Meier C, Radimerski T, Iten F, Kranzlin M, Muller-Brand J, de Groot JWB, Kema IP, Links TP, Müller B, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010; 116(1):31–40. doi:10.1002/cncr.24738.
  • Avrillon V, Locatelli-Sanchez M, Folliet L, Carbonnaux M, Perino E, Fossard G, Desseigne M, Freymond N, Geriniere L, Perrot E, et al. Lung cancer may increase serum procalcitonin level. Infect Disord Drug Targets. 2015; 15(1):57–63. doi:10.2174/1871526515666150320162950.
  • Pardo-Cabello AJ, Manzano-Gamero V. Small cell lung cancer elevates procalcitonin levels in the absence of infection. Lung Cancer. 2019. 134:134 272–273. doi:10.1016/j.lungcan.2019.06.018.
  • Liu D, Huang Y, Li L, Song J, Zhang L, Li W. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer. BMC Cancer. 2017;17(1):882. doi:10.1186/s12885-017-3893-1.
  • Suzuki R, Lin SH, Wei X, Allen PK, Welsh JW, Byers LA, Komaki R. Prognostic significance of pretreatment total lymphocyte count and neutrophil-to-lymphocyte ratio in extensive-stage small-cell lung cancer. Radiother Oncol. 2018;126(3):499–505. doi:10.1016/j.radonc.2017.12.030.
  • Kang MH, Go SI, Song HN, Lee A, Kim SH, Kang JH, Jeong B-K, Kang KM, Ling H, Lee G-W, et al. The prognostic impact of the neutrophil-to-lymphocyte ratio in patients with small-cell lung cancer. Br J Cancer. 2014; 111(3):452–460. doi:10.1038/bjc.2014.317.
  • Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiol Rev. 2019;99(2):1223–1248. doi:10.1152/physrev.00012.2018.
  • Wasamoto S, Imai H, Tsuda T, Nagai Y, Minemura H, Yamada Y, Umeda Y, Kishikawa T, Shiono A, Kozu Y, et al. Pretreatment glasgow prognostic score predicts survival among patients administered first-line atezolizumab plus carboplatin and etoposide for small cell lung cancer. Front Oncol. 2022; 12:1080729. doi:10.3389/fonc.2022.1080729.
  • Kutlu Y, Aydin SG, Bilici A, Oven BB, Olmez OF, Acikgoz O, Hamdard J. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as prognostic markers in patients with extensive-stage small cell lung cancer treated with atezolizumab in combination with chemotherapy. Medicine (Baltimore). 2023;102(15):e33432. doi:10.1097/MD.0000000000033432.
  • Russwurm S, Stonans I, Stonane E, Wiederhold M, Luber A, Zipfel PF, Deigner H-P, Reinhart K. Procalcitonin and CGRP-1 mrna expression in various human tissues. Shock. 2001;16(2):109–112. doi:10.1097/00024382-200116020-00004.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.